News and Press Releases
Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies
Bexicaserin achieved an overall median seizure reduction of 59.3 percent in countable motor seizures over a 12-month open-label extension (OLE) treatment period. The treatment with bexicaserin demonstrated favorable safety and...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2025
Phesi announces AI-driven Trial Accelerator platform hits new milestone with data from 132 million patients
Latest version of Trial Accelerator™ incorporates new AI capabilities and product features to unlock a patient-centric approach to trial design and implementation 29 January 2025 -- Boston, US -- Phesi,...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2025
Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications
Cognizant will provide AI-driven solutions to enhance customer service, employee engagement, and business value 30 January 2025 -- New Jersey, US -- Cognizant has announced an expansion of its longstanding relationship...
Category: Biotechnology, Drug Discovery, Logistics, Other, Pharmaceutical
Posted: January 30, 2025
Office Cognizant Technology Solutions World Headquarters Glenpointe Centre West 500 Frank W Burr Blvd Teaneck 07666 NJ
Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics
30 January 2025 -- Espoo, Finland -- Orion Corporation and Invenra Inc, an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today announced that they have entered into...
Category: Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2025
Owkin Announces First Patient Dosed in Phase I AI-optimized Clinical Trial of OKN4395, a First-in-Class EP2/EP4/DP1 Triple Inhibitor for Patients with Solid Tumors
OKN4395 is the first Owkin development program to leverage K1.0, Owkin’s AI-powered Operating System, from asset selection to clinical development optimization This asset is a highly selective triple inhibitor of...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 30, 2025
Rentschler Biopharma announces strategic realignment of its global business operations
30 January 2025 – Laupheim, Germany – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today a realignment of its global business operations...
Category: BioManufacturing
Posted: January 30, 2025
ENA Respiratory Successfully Completes Phase Ib Dosing of Antiviral Host Defense Immune Enhancer INNA-051 Dry Powder Formulation in Older Adults and Advances Study in Young Adults
New intranasal formulation with significantly improved stability was well-tolerated and led to local activation of innate immune pathways in adults aged >60 U.S. Department of Defense (DOD) funded study extension...
Category: Clinical Trials, Drug Delivery
Posted: January 29, 2025
Image Analysis Group Announces Release of DYNAMIKA V.7, their Award-Winning Cloud Platform for Clinical Trial Imaging
DYNAMIKA V.7 has achieved the British Standards Institute (BSI) surveillance audit certification following a recent SOC II Type I compliance certification 29 January 2025 -- London, UK -- Image Analysis...
Category: Clinical Trials, Drug Discovery, Other
Posted: January 29, 2025
NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing platform
Findings in lung cancer show that CTCs can provide additional biomarkers not found in ctDNA from single blood sample ANGLE invited to present data at EACR-Illumina webinar on 6 February...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: January 29, 2025
Nemera awarded EcoVadis gold medal: a recognition of its commitment to sustainable development
28 January 2025 – Lyon, France – Having been awarded the silver medal since 2020, Nemera has reached a significant milestone in 2024 by obtaining the EcoVadis gold medal, with...
Category: Drug Delivery, Manufacturing and Packing
Posted: January 28, 2025
Sphere Fluidics launches Cyto-Mine Chroma and announces Early Access Program
Researchers invited to gain early access to next-generation platform to optimize functional single-cell analysis workflows across expanded applications in life science R&D 27 January 2025 – Cambridge, UK – Sphere...
Category: BioManufacturing
Posted: January 28, 2025
The Jonas Webb Building, Babraham Research Campus, Babraham, Cambridge CB22 3AT, United Kingdom
Schrödinger Selects Sapio Sciences to Enhance In Silico Drug Discovery From Plasmid to Structure
Configurable informatics platform improves lab efficiency, data tracking, and resource management from plasmid to structure 28 January 2025 – Baltimore, MD, US – Sapio Sciences, the science-aware™ lab informatics platform,...
Category: BioManufacturing, Drug Discovery
Posted: January 28, 2025
Medable Reports 80% Revenue Growth from Portfolio-Level eCOA Adoption, Sharp Increase Compared to Study-by-Study Adoption
Growing industry confidence drives shift in digital strategy for clinical trial sponsors 28 January 2025 -- California, US -- Medable Inc., a leading provider of clinical development technology, today announced 80%...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 28, 2025
New Data Reveals Decentralized Clinical Trials Linked to Improved Diverse Participation Across Many Underrepresented Demographics
Asian participation increased by 6 percentage points; American Indian/Alaska Native participation quadrupled; Female participation rose from 49.0% to 55.7% 28 January 2025 -- California, US -- Medable Inc., a leading provider...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 28, 2025
Phillips Medisize Expands Its Inhalation Drug Delivery Capabilities
Molex, a parent to Phillips Medisize, Closes Acquisition of Vectura Group Ltd. Phillips Medisize adds market-leading inhalation capabilities to its existing suite of drug delivery device design and production capabilities. ...
Category: Drug Delivery, Manufacturing and Packing
Posted: January 28, 2025
